Altered expression of cell cycle and apoptotic proteins in human liver pathologies

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4493-4501

  Mitselou, Antigony ^a   Karapiperides, Damianos ^b   Nesseris, Ioannis ^a   Vougiouklakis, Theodoros ^a   Agnantis, Niki J ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b Agios Dimitrios Hospital   (Greece)

Author keywords

Apoptotic proteins; Cell cycle proteins; Cirrhosis; Hepatitis; Hepatocellular carcinoma

Indexed keywords

FORMALDEHYDE; KI 67 ANTIGEN; PARAFFIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DISEASE COURSE; EMBEDDING; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEATOSIS;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FATTY LIVER; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650230180     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Callea F, Brisigotti M, Fabbretti G, Sclot R, Van Eyken P and Favret M: Cirrhosis of the liver: a regenerative process. Dig Dis Sci 36: 1287-1293, 1991.
2. Kawasaki S, Imamunra H, Bandal Y, Sanjo K and Idezuki Y: Direct evidence for the intact hepatocyte theory in patients with liver cirrhosis. Gastroenterology 102: 1351-1355, 1992.
3. Farinati E, Cardin R, D'Errico A, DeMaria N, Naccarato R, Cecchetto A and Grigioni W: Hepatocyte proliferative activity in chronic liver damage as assessed by the monoclinal antibody MIB1 Ki-67 in archival material: The role of etiology disease activity, iron, and lipid peroxidation. Hepatology 23: 1468-1475, 1996.
4. Delhaye M, Louis H, Degraef C, Le Moine O, Deviere J, Gulbis R, Jacobovitz D, Adler M and Galand P: Relationship between hepatocyte proliferative activity and liver functional reserve in human cirrhosis. Hepatology 23: 1003-1011, 1996.
5. Morgan DO: Principles of CDK regulation. Nature 374: 131-134, 1995.
6. Pines J: Cyclins and cyclin-dependent kinases: a biochemical view. Biochem J 308: 697-711, 1995.
7. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
8. Sclafani RA: Cyclin-dependent kinase-activating kinases. Curr Opin Cell Biol 8: 788-794, 1996.
9. 1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995.
10. Li CY, Suardet L and Little JB: Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. J Biol Chem 270: 4971-4976, 1995.
11. Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev 10: 3065-3075, 1996.
12. La Baer J, Garrett MD, Stevenson LF, Slingerland JM, Sanfho C, Chu HS, Fattaey A and Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev 11: 847-862, 1997.
13. Soos TJ, Kiyokawa H, Yan JS, Rubin MS, Giordano A, DeBlasio A, Bottega S, Wong B, Mendelsohn J and Koff A: Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ 7: 135-146, 1996.
14. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
15. Oren M: Regulation of the p53 tumor suppressor protein. J Biol Chem 274: 36031-36034, 1999.
16. Schafer T, Schever C, Roemer K, Menger MD and Vollmar B: Inhibition of p53 protects liver tissue against endotoxin-induced apoptotic and necrotic cell death. FASEB J 17: 660-667, 2003.
17. Sola S, Ma X, Castro RE, Kren BT, Steer CJ and Rodriguez CM: Ursodeoxycholic acid modulates E2F-1 and p53 expression through a caspase-independent mechanism in transforming growth factor beta1-induced apoptosis of rat hepatocytes. J Biol Chem 278: 48831-48838, 2003.
18. Hengartner MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
19. Feldman G: Liver apoptosis. J Hepatlo Suppl 2: 1-11, 1997.
20. Tang ZY: Hepatocellular carcinoma: cause, treatment and metastasis. World J Gastroenterol 7: 445-454, 2001.
21. Coleman WB: Mechanisms of human hepatocarcinogenesis. Curr Mol Med 3: 573-588, 2003.
22. Albrecht JH, Poon R, Ahonen CL, Rieland BM, Deng C and Crary GS: Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver. Oncogene 16: 2141-2150, 1998.
23. Varli M, Okcu Heper A, Erden E, Uzunalimoglu O, Yurdaydin C and Bozkaya H: P21 expression and its relation to disease activity and hepatocyte proliferation in chronic hepatitis B virus infection. Turk J Gastroenterol 16: 12-16, 2005.
24. WAF1/CIP1 protein expression is predominantly related to altered p53 in hepatocellular carcinomas. Br J Cancer 83: 5-55, 2000.
25. CIP1/WAF1 in monocytic differentiation. EMBO J 5: 1223-1234, 1999.
26. WAF1/CIP1 expression in human hepatocellular carcinomas. Liver Int 26: 1018-1019, 2006.
27. Russo AA, Jeffrey PD, Patten A, Massague J and Pavletick NP: Crystal structure of the p27/kip1 cyclin-dependent kinase inhibitor bound to the cyclin -Cd2 complex. Nature 382: 325-331, 1996.
28. Pagano M, Tam SW, Theodoras AM, Romero-Beer P, Del Sal G, Chau V, Yew R, Draetta G and Rolfe M: Role of the ubiquitin-preoteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685, 1995.
29. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M and Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (T Ia, b) invasive breast carcinomas. Cancer Res 57: 1259-1263, 1997.
30. Thomas GV, Szigeti K, Murphy M, Draetta G, Pagano M and Loda M: Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastasis. Am J Pathol 153: 681-687, 1998.
31. Cordon-Cardo J, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massagne J and Scher HI: Distinct altered patterns of p27/kip1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 90: 1284-1291, 1998.
32. Osoegawa A, Yoshino I, Tanaka S, Sugio K, Kameyama T, Yamaguchi M and Maehuara Y: Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. J Clin Oncol 15: 4166-4173, 2004.
33. Peschos D, Tsanou E, Stefanou D, Damala C, Vougiouklakis T, Mitselou A and Agnantis JN: Expression of cyclin-dependent kinases inhibitors p21 (WAF1) and p27 (KIP1) in benign, premalignant and malignant laryngeal lesions: Correlation with cell cycle regulatory proteins. In Vivo 18: 719-724, 2004.
34. Hui AM, Sun L, Kanai Y, Sakamoto M and Hirohashi S: Reduced p27/kip1 expression in hepatocellular carcinomas. Cancer Lett 132: 67-73, 1998.
35. Yachida S, Sakamoto M, Imaida K, Yokohira M, Saoo K, Okano K, Wakabayashi H, Maeta H and Suzuki Y: P27/kip1 is overexpressed in very early stages of hepatocarcinogenesis. Cancer Sci 99: 2152-2159, 2008.
36. Charlotte F, L'Hermine A, Martin N, Geleyen Y, Noliet M, Gaurlard P and Zafrani ES: Immunohistochemical detection of BCL-2 protein in normal and pathological human liver. Am J Pathol 144: 460-465, 1994.
37. Skopelitou A, Hadjiyannakis M, Alexopoulou V, Krikoni O, Kamina S and Agnantis N: Topographical immunohistochemical expression of BCL-2 protein in human liver lesions. Anticancer Res 16: 975-978, 1996.
38. Mitselou A, Ioachim E, Kitsou E, Vougiouklakis T, Zagorianakou N, Makrydimas G, Stefanaki S and Agnantis NJ: Immunohistochemical study of apoptosis related BCL-2 protein and its correlation with proliferation indices (Ki-67 and PCNA), tumor suppressor genes (p53, pRB), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium. In Vivo 17: 469-478, 2003.
39. Mitselou A, Peschos D, Dallas P, Charalabopoulos K, Agnantis NJ and Vougiouklakis T: Immunohistochemical analysis of BCL-2 protein in papillary carcinoma and papillary microcarcinomas of the thyroid gland. Exp Oncol 26: 282-286, 2004.
40. Koga H, Sakisaka S, Ohishi M, Sata M and Tanikawa K: Nuclear DNA fragmentation and expression of BCL-2 in primary biliary cirrhosis. Hepatology 25: 1077-1084, 1997.
41. Green DR: Apoptotic pathways: paper wraps stone blunts scissors. Cell 102: 1-4, 2000.
42. Panasiuk A, Dzieciol J, Panasiuk B and Prokopowicz D: Expression of p53, BAX, and BCL-2 proteins in hepatocytes in non-alcoholic fatty liver disease. World J Gastroenterol 12: 6198-6202, 2006.
43. Ramalho R, Cortez-Pinto H, Castro RE, Sola S, Costa A, Moura MC, Camilo ME and Rodrigues CM: Apoptosis and BCL-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol 18: 21-29, 2006,
44. Garcia EJ, Lawson D, Cotsonis G and Cohen C: Hepatocellular carcinoma and markers of apoptosis (BCL-2, BAX, BCL-X): prognostic significance. Appl Immunohistochem Mol Morphol 10: 210-217, 2002.
45. Yoon DS, Cheong JH, Park YN, Kwon SW, Chi HS and Kim BR: Cell proliferation index and the expression of p53 and BCL-2 in tumorous and non-tumorous lesions of hepatocellular carcinoma and metastatic liver cancer. Yomei Med J 39: 424-429, 1998.
46. Yahagi N, Shimano H, Matsuzaka T, Sekiya M, Najima Y, Okazaki S, Okasaki H, Tamura Y, Iizuka Y, Inove N, Nakagawa Y, Takeuchi Y, Ohashi K, Harada K, Gotada T, Nagar R, Kadowaki T, Ishibashi S, Osuga J and Jamada N: P53 involvement in the pathogenesis of fatty liver disease. J Biol Chem 279: 20571-20575, 2004.
47. Nagao T, Kondo F, Sato T, Nagato Y and Kondo Y: Immunohistochemical detection of aberrant p53 expression in hepatocellular carcinoma: correlation with cell proliferative activity indices, including mitotic index and MIB-1 immunostaining. Human Patholog 26: 326-333, 1995.
48. Qin LF, Ng I, Fan ST and Ng M: P21/WAF1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int J Cancer 79: 424-428 1998.
49. Ojanguren I, Arisa A, Llatjos M, Castella E, Mate JI and Navas-Palacios JJ: Proliferating cell nuclear antigen expression in normal, regenerative, and neoplastic liver: a fine-needle aspiration cytology and biopsy study. Human Pathol 24: 905-908, 1993.
50. Nolte M, Werner M, Nasarek A, Bektas H, von Wasielewski R, Klempnauer J and Georgii A: Expression of proliferation-associated antigens and detection of numerical chromosome aberrations in primary liver tumours: relevance to tumour characteristics and prognosis. J Clin Pathol 51: 47-55, 1998.
51. Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S and Mondelli M: Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 69: 1145-1156, 1990.